Akebia Therapeutics (AKBA)
NASDAQ:AKBA
AKBA Stock Chart & Stats
$1.47
$0.30(14.49%)
At close: 4:00 PM EST
$1.47
$0.30(14.49%)
Day’s Range― - ―
52-Week Range$1.14 - $4.08
Previous CloseN/A
Volume5.66M
Average Volume (3M)2.54M
Market Cap
$375.03M
Enterprise Value$425.24M
Total Cash (Recent Filing)$184.84M
Total Debt (Recent Filing)$216.30M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding267,879,240
10 Day Avg. Volume1,884,221
30 Day Avg. Volume2,544,851
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)12.70
Price to Sales (P/S)1.75
P/FCF Ratio6.09
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda19.57
Forecast
1Y Price Target
$4.67Price Target Upside217.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$242.73M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst believes outcome-focused clinical data and head-to-head comparisons versus existing therapies could increase payer and provider confidence and strengthen the drug's market differentiation.
Dialysis Commercialization And AdherenceAnalyst highlights commercial supply agreements with major dialysis organizations and an in-center dosing protocol that improved first refill adherence, supporting higher patient utilization of the anemia therapy.
Pipeline Expansion Into Rare Kidney DiseasesAnalyst points to a diverse pipeline including praliciguat and a tissue-targeted complement inhibitor that target rare kidney conditions and novel mechanisms, offering potential growth beyond the core anemia franchise.
Bears Say
Clinical Trial Outcome RiskAnalyst notes that commercial and clinical success depends on upcoming trial results and published comparative evidence, and failure to demonstrate clear differentiation could limit market uptake.
Generic Competition PressureAnalyst cautions that current marketed drugs face generic competition, which could reduce revenues and pose a headwind to the company's financial outlook.
Inventory And Near-term Revenue ImpactAnalyst lowered the price target after adjusting near-term revenue expectations to reflect an inventory impact tied to a dosing protocol at a large dialysis provider, signaling potential short-term revenue weakness.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $1.14 and its highest was $4.08 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $375.03M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 27 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.036 by -$0.014.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 267,879,240 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.036. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (217.69% Upside)
$4.67 (217.69% Upside)
Blogger Sentiment
Bullish
AKBA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 229.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $86.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
-16.70%
Trailing 12-Months
Asset Growth
70.65%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantive progress: a successful commercial launch of Vafseo with meaningful early prescriber traction and access, significant year-over-year revenue growth (~47%) and a materially improved balance sheet (cash up to $184.8M), supported by promising clinical and cost data that could drive longer-term adoption. Offsetting these positives were slower adoption in H2 2025, a one-time $4.8M inventory drawdown related to an in-center dosing transition, rising R&D spend (including a $12.8M acquired R&D charge) and expected 2026 pressure on Auryxia from generics. Overall the positives (revenue growth, cash position, clinical evidence, expanding prescriber/access and pipeline catalysts) outweigh the near-term operational and competitive headwinds.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$4.67
▲(217.69% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.85% Insiders
9.47% Mutual Funds
2.53% Other Institutional Investors
71.35% Public Companies and Individual Investors